Logo_AIHTA
  • Deutsch
  • Contact
    • Imprint
      • Privacy Notice
        • Newsletter
          • Sitemap
            Menu_button
            • News
              • About us
                • Research areas
                  • Research Projects
                    • Publications
                      • Search
                        • Job advertisement in AIHTA - Research Associate Senior
                          • Announcements
                            • Events
                              • Newsletter
                                • Press release on our reports
                                  Video
                                  Video: What is HTA?    
                                  • Home
                                  • News
                                  • Announcements

                                  Announcements

                                  Fotoleiste-1b

                                   

                                  Current & archive

                                  2140
                                  ©Juan Gärtner

                                  Horizon Scanning in Oncology - Reports

                                  We are pleased to introduce our new HSO report.

                                  DSD HSO No. 89
                                  Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs)

                                  More...

                                  Adobestock-137317687
                                  ©jean song

                                  Custom-made or customisable 3D printed implants and cutting guides versus non- 3D printed standard implants and cutting guides for improving outcome in patients undergoing knee, maxillofacial, or cranial surgery

                                  3D printed custom-made or customisable implants and cutting guides are currently most frequently applied in knee, maxillofacial, and cranial surgery. Evidence of very low or low quality shows significant differences in precision in terms of malalignment and deviation between 3D printed technology and standard instrumentation in knee arthroplasty. Evidence of higher quality is needed to validate these significant results and draw final conclusions. No firm conclusions can be made in mandibular reconstruction and cranioplasty, since no outcomes were significant in favour of either technology. No statements regarding long-term safety outcomes can be made.

                                  Publication: LBI-HTA Projektbericht Nr. 117:  https://eprints.aihta.at/1209/

                                  Contact: Sabine Ettinger

                                  More...

                                  2416
                                  ©AdobeStock

                                  Evaluation of individual medical procedures 2019 - Reports

                                  We are pleased to introduce our new reports.

                                  Decision Support Documents 2019:

                                  • DSD 115: Osteochondral allograft transplantation for the knee (or other joints)
                                    https://eprints.aihta.at/1204
                                  • DSD 116: Allograft for anterior and posterior cruciate ligament reconstruction
                                    https://eprints.aihta.at/1205
                                  • DSD 117: Human dermal allograft for massive rotator cuff tears
                                    https://eprints.aihta.at//1206
                                  • DSD 118: 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
                                    https://eprints.aihta.at/1207

                                  +4 Updates:

                                  • DSD 65/1. Update 2019: Annulus Fibrosus Repair after lumbar discectomy https://eprints.aihta.at/1200
                                  • DSD 98/1. Update 2019: Single-/two-step scaffold-based cartilage repair in the knee and ankle joint
                                    https://eprints.aihta.at/1201
                                  • DSD 99/1. Update 2019: Radiofrequency denervation for lumbar and cervical facet joint pain – a systematic review
                                    https://eprints.aihta.at/1202
                                  • DSD 100/1. Update 2019: Upper Airway Stimulation for Moderate-to-Severe Sleep Apnea
                                    https://eprints.aihta.at/1203

                                   

                                  More...

                                  2139
                                  ©Juan Gärtner

                                  Horizon Scanning in Oncology - Reports

                                  We are pleased to introduce our new HSO report.

                                  DSD HSO No. 88
                                  Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC)

                                  More...

                                  Fotolia-76406533-m33

                                  Robot-assisted surgery in thoracic and visceral indications

                                  In robot-assisted surgery, the surgeons control the surgical instruments with a telemanipulator. The aim of our report was to investigate the efficacy and safety of robotic surgery compared to open surgery as well as conventional laparoscopy in thoracic and visceral indications. A total of 13 indications were investigated. There was insufficient evidence for the evaluation of efficacy in nine indications. Statements on effect were possible only for some of the outcomes in only four of the procedures (oesophagectomy, gastrectomy, rectal resection,cholecystectomy), for which the quality of the evidence was rated low to moderate. Since the current evidence is not sufficient to determine the added value of robot-assisted surgery compared to conventional surgical procedures, results of ongoing studies are awaited.

                                  Publication: LBI-HTA Project report No. 108: https://eprints.aihta.at/1198/

                                  Contact: Louise Schmidt

                                  More...

                                  Fotolia-115223963-m21

                                  Advanced Therapy Medicinal Products (ATMP): Technology forecast

                                  Advanced Therapy Medicinal Products" (ATMP) is the umbrella term for three classes of medicinal products: somatic cell therapy medicinal products, gene therapy medicinal products and biotechnologically processed tissue preparations [also known as tissue engineering products (TEP)], as well as combination products. These drugs contain or mostly consist of living cells or tissues and are therefore highly complex. The cells used are often taken from a patient, processed in the laboratory (e.g. increased or genetically modified) and then administered again to the same patient.

                                  The review of the LBI-HTA (published only as an English publication, not as a report) gives an overview of applications of ATMP products shortly before or after their market launch.

                                  Publication: Article

                                  Contact: Claudia Wild

                                  More...

                                  Fotolia-82047558-m1

                                  Evaluation methods for the benefit assessment of easily accessible, out-patient health centers for vulnerable groups - Target group focus: Homeless and non-insured people

                                  Vulnerable groups, such as homeless and non-insured people, have a poorer physical and mental health status than comparable populations and usually have no or difficult access to standard health care. Social organisations provide basic health and social care services for these groups of people. Against this background, we searched for evaluation methods for the benefit assessment of easily accessible, outpatient health centers and described the methods, indicators, and instruments used in evaluation studies and reports of comparable services.

                                  Publication: LBI-HTA Project report No. 114: https://eprints.aihta.at/1195/

                                  Contact: Roman Winkler, Inanna Reinsperger

                                  More...

                                  Adobestock-228357589

                                  C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections

                                  Infection markers such as the C-reactive protein (CRP) can be used in addition to the clinical diagnosis of an infectious disease. So far, CRP tests have been carried out in the laboratory; CRP "point-of-care-testing" (POCT) refers to measurements close to the patient in primary care. The result is available within minutes. CRP POCT is intended to assist the physician to rule out a severe bacterial infection and support a decision on the need for antibiotic prescription.

                                  Publication: LBI-HTA Project report No. 116: https://eprints.aihta.at/1194/

                                  Contact: Sabine Ettinger

                                  More...

                                  2138

                                  Horizon Scanning in Oncology - Reports

                                  We are pleased to introduce our two new HSO reports.

                                  DSD HSO No. 86
                                  Olaparib (Lynparza®) as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer

                                  DSD HSO No. 87
                                  Atezolizumab (Tecentriq®) with nab-paclitaxel (Abraxane®) for the treatment of advanced triple-negative breast cancer (aTNBC)

                                  More...

                                  Adobestock-213272598

                                  Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease)

                                  CAD is a disease defined as the manifestation of arteriosclerosis in the coronary arteries and is the leading cause of death in Europe. This systematic review evaluates the current evidence on the efficacy and safety of bioresorbable stents, the latest generation of stents in percutaneous coronary intervention (PCI) in the treatment of CAD, compared to traditional revascularisation strategies (PCI with permanent metal stents or coronary artery bypass graft surgery).

                                  Based on evidence from eight RCTs, the fully bioresorbable everolimus-eluting stent Absorb® BVS is considered to be less effective and to have a worse safety profile compared with everolimus- or biolimus-eluting permanent metal stents. There is insufficient evidence to determine whether Absorb® BVS is considered less effective or less safe than other revascularisation strategies. There is insufficient evidence to determine whether the other four currently CE-certificated fully bioresorbable sent systems [DESolve®, Magmaris (Dreams 2G), Art Pure or Fantom®] are more effective than (or at least as effective as) and/or have better (or at least similar) safety profiles compared with drug-eluting permanent metal stents or other revascularisation strategies.

                                  Publication: Decision Support Document No. 81/1.Update: https://eprints.aihta.at/1191/

                                  Contact: Judit Erdos

                                  More...

                                  « < ... 18 19 20 21 22 ... > »
                                  Displaying results 191 to 200.
                                  • News
                                    • Job advertisement in AIHTA - Research Associate Senior
                                      • Announcements
                                        • Events
                                          • Newsletter
                                            • Press release on our reports
                                            • About us
                                              • Scientific Advisory Board
                                                • Evaluation
                                                  • History
                                                    • Methods
                                                      • Team
                                                        • External experts
                                                          • Shareholder & organization chart
                                                          • Research areas
                                                            • Oncology
                                                              • High tech medicine
                                                                • Rehabilitation and occupational therapy
                                                                  • Prevention and screening
                                                                    • Psychological & psychiatric interventions
                                                                      • Health economics
                                                                        • European collaboration
                                                                          • HTA-methods & steering instruments
                                                                            • Complementary medicine
                                                                            • Research Projects
                                                                              • Synopsis of current research projects
                                                                                • Synopsis of completed research projects
                                                                                  • Decision Support Documents for the Austrian Appraisal Board
                                                                                    • HTA-Information Service Rapid Reviews
                                                                                      • Horizon Scanning in Oncology – Prioritisation of new and emerging oncologic drugs
                                                                                        • Horizon Scanning of Medicines - Reports and Fact Sheets
                                                                                          • Horizon Scanning in Oncology – support for a budget-impact-calculation
                                                                                            • Evaluation of individual medical procedures - Reports
                                                                                              • Master's theses supervision
                                                                                                • All projects in an overview
                                                                                                • Publications
                                                                                                  • Repository
                                                                                                    • HTA-Newsletter
                                                                                                      • Annual Reports
                                                                                                      • Search
                                                                                                        Netzwerk
                                                                                                        • Ebm
                                                                                                        • Inahta
                                                                                                        Shareholder
                                                                                                        • Bmfg
                                                                                                        • Sv
                                                                                                        • Wgfond
                                                                                                        • Noe
                                                                                                        • Ooghfond
                                                                                                        • Ghls
                                                                                                        • Tirol
                                                                                                        • Vorarlberg
                                                                                                        • Kghfond
                                                                                                        • Ghpf
                                                                                                        • Burgef
                                                                                                        • Contact
                                                                                                          • Imprint
                                                                                                            • Privacy Notice
                                                                                                              • Newsletter
                                                                                                                • Sitemap
                                                                                                                  © 2026 HTA Austria - Austrian Institute for Health Technology Assessment GmbH. Alle Rechte vorbehalten.
                                                                                                                  • Log in